To encourage domestic manufacturing and secure access to life-saving medications, President Trump has imposed a 100% tariff on brand-name pharmaceuticals produced abroad. Drug companies that commit to relocating production to the U.S. will face a transitional 20% tariff, with the full tariff levied if production does not return to the U.S. within four years. Companies that also agree to lower prices to “most favored nation” levels will be exempt from tariffs, signaling the administration’s continued efforts to negotiate deals and incentivize U.S. investment in the pharmaceutical sector.
Read More
The publication is seeking financial support from its readers to maintain its operations. Declining advertising revenue has created a funding shortfall, threatening the continuation of its independent and unbiased journalism. Readers who value the publication’s reporting are encouraged to contribute. Their support will help ensure the availability of accurate and meaningful news for all.
Read More
In response to a national security investigation launched April 1st, President Trump plans to announce pharmaceutical tariffs within the next two weeks. These tariffs aim to incentivize the repatriation of pharmaceutical production to the United States, significantly impacting countries like Britain and Ireland, which boast large pharmaceutical trade surpluses with the U.S. The impending tariffs are particularly concerning for major UK-based pharmaceutical companies like GSK and AstraZeneca, who have already engaged in intense lobbying efforts to mitigate potential losses. While a previous 10% tariff on most imports was temporarily averted for pharmaceuticals, this new announcement suggests a more aggressive protectionist strategy.
Read More
President Trump announced an impending “major” tariff on imported pharmaceuticals, aiming to encourage domestic production. He further asserted that Taiwan Semiconductor Manufacturing Company (TSMC) faces a potential 100% tax if it doesn’t establish U.S. plants, criticizing a $6.6 billion government grant to TSMC as unnecessary. These actions reflect Trump’s broader strategy to bolster American manufacturing and reduce reliance on foreign goods. The pharmaceutical tariff and TSMC pressure tactics represent significant policy shifts with potentially far-reaching economic consequences.
Read More
John Q. Hosedrinker